Effects of nabumetone,celecoxib, and ibuprofen on blood pressure control in hypertensive patients on angiotensin converting enzyme inhibitors |
| |
Authors: | Palmer Robert Weiss Robert Zusman Randall M Haig Ann Flavin Susan MacDonald Brian |
| |
Affiliation: | SmithKline Beecham Pharmaceuticals, GlaxoSmithKline Pharmaceuticals, Collegeville, Pennsylvania 19426-0989, USA. |
| |
Abstract: | ![]() Nonsteroidal anti-inflammatory drugs interfere with certain antihypertensive therapies. In a double-blind study, 385 hypertensive patients stabilized on an angiotensin converting enzyme inhibitor were treated with nabumetone, celecoxib, ibuprofen, or placebo for 4 weeks. Ibuprofen caused significantly greater increases in systolic (P < .001) and diastolic (P < .01) blood pressures (BPs) compared to placebo, but not nabumetone or celecoxib. The proportion of patients with systolic BP increases of clinical concern at end point was significantly higher (P < .001) for the ibuprofen group (16.7%; 15 of 90), but not for the nabumetone group (5.5%; 5 of 91) or the celecoxib group (4.6%; 4 of 87) compared to the placebo group (1.1%; 1 of 91). |
| |
Keywords: | |
本文献已被 ScienceDirect PubMed 等数据库收录! |
|